Nathan Kline Institute for Psychiatric Research
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Nathan Kline Institute for Psychiatric Research sits in the top decile of US sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count).
Nathan Kline Institute for Psychiatric Research: 20 sponsored US clinical trials, 1 recruiting.
Nathan Kline Institute for Psychiatric Research sponsors 20 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 18 completed. 7 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 4 trials.
Top-decile sponsor footprint
Nathan Kline Institute for Psychiatric Research ranks in the top decile of sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
18 of 19 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
20 total, page 1 of 1
Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual Pathways
NCT07469384
D-serine and Cognitive Remediation in Schizophrenia
NCT02156908
Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic
NCT02128919
Biomarkers in Schizophrenia
NCT00817336
D-serine for the Schizophrenia Prodrome
NCT00826202
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors
NCT00802919
Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain
NCT00709202
Sodium Oxybate in Schizophrenia With Insomnia
NCT00594256
Metformin for Weight Loss in Schizophrenia
NCT01177709
Varenicline Effects In Schizophrenic Smokers
NCT00548470
Safety and Effectiveness of D-serine in Schizophrenia
NCT00322023
Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia
NCT00231894
Effect of High-Dose B-Complex Vitamins on the Symptoms of Schizophrenia
NCT00403247
Adjunctive Glycine for Obsessive Compulsive Disorder
NCT00405535
Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism
NCT00287820
Cognitive Skills Training Using Computer for Patients With Severe Mental Illness
NCT01036282
The Impact of Family CTI on Homeless Children
NCT00055081
Lorazepam-Induced Toxicity in the Aged
NCT00044642
Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility
NCT00308360
Clozapine and Olanzapine Treatment of Aggression
NCT01123408
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 6 |
| Phase 4 | 7 |
Therapeutic Areas
What is open in the Nathan Kline Institute for Psychiatric Research pipeline
1 recruiting of 20 indexed (5% open); 18 completed (90%).
Phase mix: 7 late (III/IV) vs 6 early (I/II) (balanced across stages).
Top condition: Schizophrenia (4 trials), 7 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Nathan Kline Institute for Psychiatric Research: open-pipeline peers nationwide
Peers matched on 20 registered trials and 5% open enrollment, not the therapeutic-area sidebar.
Nathan Kline Institute for Psychiatric Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 20 trials (± recruiting share)
- 59th Medical Wing · 20 trials · 15% recruiting
- Abiomed · 20 trials · 10% recruiting
- Agency for Healthcare Research and Quality (AHRQ) · 20 trials · 0% recruiting
- Alliance Foundation Trials · 20 trials · 15% recruiting
Sponsors near 5% open enrollment (± trial volume)
- Avera McKennan Hospital & University Health Center · 5% recruiting · 20 trials
- HonorHealth Research Institute · 5% recruiting · 20 trials
- Integra LifeSciences Corporation · 5% recruiting · 60 trials
- Lumenis Be · 5% recruiting · 20 trials
Related
What to do with this Nathan Kline Institute for Psychiatric Research page
20 registered trials is a research-attention snapshot, not an endorsement of Nathan Kline Institute for Psychiatric Research or any single study.
- 1 of Nathan Kline Institute for Psychiatric Research's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Schizophrenia is the condition Nathan Kline Institute for Psychiatric Research studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Nathan Kline Institute for Psychiatric Research pipeline card: 20 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.